In a somber end to an FDA advisory committee’s two-day scouring of multiple drugmakers’ oncology data, Pfizer’s pitch to ...

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.

May 19 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said it would license an experimental cancer treatment from China's 3SBio Inc (1530.HK), opens new tab, paying $1.25 billion upfront ...

WASHINGTON — The release of COVID-19 vaccine results after the 2020 election may have not been a “coincidence” — and could have been part of an effort by senior Pfizer executives to ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...

Pfizer (PFE) reported mixed first quarter earnings Tuesday, as the company focuses on gaining investor interest in its near-term pipeline amid a volatile macro environment in the markets. Pfizer ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.